Longitudinal change in c-terminal fibroblast growth factor 23 and outcomes in patients with advanced chronic kidney disease

Table 2 Cox-regression models for outcomes

	All-cause mortality prior RRT		Renal Replacement Therapy (RRT)		Cardiovascular event
	HR (95% CI)	p-Value	HR (95% CI)	p-Value	HR (95% CI)	p-Value
Univariate model
Quartile 1	Reference	–	Reference	–	Reference	–
Quartile 2	0.65 (0.31-1.38)	0.267	0.63 (0.22 -1.82)	0.40	0.72 (0.28-1.84)	0.493
Quartile 3	1.13 (0.87-1.65)	0.270	1.15 (0.74-1.79)	0.54	1.29 (0.86-1.94)	0.207
Quartile 4	1.43 (1.16-1.75)	0.001	2.01 (1.56-2.56)	< 0.001	1.31 (0.99-1.74)	0.053
Multivariate model 1
Quartile 1	Reference	–	Reference	–
Quartile 4	1.46 (1.16-1.83)	0.001	2.06 (1.60-2.6)^a	< 0.001
Multivariate model 2
Quartile 1	Reference	–	Reference	–
Quartile 4	1.49 (1.18-1.89)	0.001	2.34 (1.57-3.47)	< 0.001

HR hazard ratio, CI confidence interval
Multivariate model 1: adjusted for clinical variables at baseline (age, smoker, diabetes, cardiovascular events, heart failure, systolic blood pressure), and cFGF23 quartiles
Multivariable model 2: adjusted for laboratory variables at baseline (MDRD eGFR, phosphate, albumin, haemoglobin, parathormone, cFGF23) and cFGF23 quartiles
^aMultivariate model 1: adjusted for clinical variables (age, gender), and cFGF23 quartiles

ISSN: 1471-2369